Hanmi Vows Not to Supply Amodipine at Significantly Low Price Level

Published: 2005-03-28 06:58:00

Updated: 2005-03-28 06:58:00

In response to the outcome from the open competitive tendering for the Veterans Hospital Network, where the winning bid for Hanmi Pharmaceutical's Amodipine was significantly below the general market price level, the company has reportedly made a decision not to supply the medication.

In the c...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK